NASDAQ:VRUS - Pharmasset Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0031 0.00 (0.00 %)
(As of 12/9/2018 01:59 PM ET)
Previous Close$0.0031
Today's Range$0.0025 - $0.0031
52-Week Range$0.0008 - $0.0120
Volume10.01 million shs
Average Volume39.80 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharmasset, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections. The Company focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. The Company has three clinical-stage product candidates. It also has a series of preclinical candidates in preparation for clinical development. The three clinical product candidates include RG7128, PSI-7977 and PSI-938. In January 2012, Gilead Sciences, Inc. acquired Pharmasset, Inc.

Receive VRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VRUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:VRUS
Previous Symbol
CUSIPN/A
WebN/A
Phone+1-609-6134100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Pharmasset (NASDAQ:VRUS) Frequently Asked Questions

What is Pharmasset's stock symbol?

Pharmasset trades on the NASDAQ under the ticker symbol "VRUS."

Has Pharmasset been receiving favorable news coverage?

Media stories about VRUS stock have been trending positive on Sunday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pharmasset earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the healthcare company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Pharmasset?

Shares of VRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharmasset's stock price today?

One share of VRUS stock can currently be purchased for approximately $0.0031.

How can I contact Pharmasset?

Pharmasset's mailing address is 303A College Rd E, PRINCETON, NJ 08540-6608, United States. The healthcare company can be reached via phone at +1-609-6134100.


MarketBeat Community Rating for Pharmasset (NASDAQ VRUS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Pharmasset and other stocks. Vote "Outperform" if you believe VRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2018 by MarketBeat.com Staff

Featured Article: Federal Reserve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel